A significantly higher proportion of patients had clinically advanced cancer stage in the GnRH antagonist treatment group (based on cancer stage, higher cancer grade, increased PSA and had “regional or metastatic” disease spread; Table 1). This evidence concerns the gene GNRH1 and cancer.